SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio editorial examining the evolution of GLP-1 treatments, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability.
The GLP-1 drug market has experienced explosive growth, with first-generation therapies like semaglutide achieving blockbuster status for diabetes and obesity. However, these drugs are associated with gastrointestinal side effects and require injectable delivery. SureNano’s GEP-44 is designed to address these limitations. According to the company, GEP-44’s triple agonist action—targeting GLP-1, PYY, and possibly other receptors—may provide enhanced efficacy while reducing side effects. Preclinical studies have shown that GEP-44 can achieve significant weight loss and blood sugar control with a more favorable tolerability profile.
SureNano Science Ltd. is a Canadian life sciences company that has acquired GlucaPharm Inc., the developer of GEP-44. The company is shifting its focus from its initial business of distributing the SureNano™ surfactant for nanoemulsions to becoming a pharmaceutical company centered on metabolic disease. The acquisition of GlucaPharm positions SureNano to compete in the rapidly growing obesity and metabolic disorder market, which is projected to reach $100 billion by 2030.
The editorial also noted that GEP-44 may offer non-injectable delivery options, which could significantly improve patient compliance. Current GLP-1 therapies are primarily injectable, and oral formulations have shown lower bioavailability. SureNano is exploring alternative delivery methods that could make the therapy more accessible to patients who avoid injections.
Investors can find the latest news and updates on SureNano Science at https://nnw.fm/SURNF. The full press release is available at https://nnw.fm/wsiDy.
The announcement underscores the growing interest in next-generation GLP-1 therapies that aim to improve upon existing treatments. As obesity rates continue to rise globally, the demand for more effective and tolerable medications is critical. SureNano’s GEP-44, with its triple agonist mechanism and potential for non-injectable delivery, could represent a significant advancement in the fight against metabolic disease.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SureNano Science’s GEP-44 Aims to Improve on First-Generation GLP-1 Drugs for Obesity and Metabolic Disorders.